Access to Medicine

EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and Coordination

Posted on by Claire Cassedy

Another matter considered during the Friday, January 30th session of the WHO Executive Board was the “Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination.” In addition to the general report on the CEWG, the EB also considered the Director General’s report on the CEWG “Health research and development demonstration projects.”

Continue Reading →

EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

Posted on by Claire Cassedy

On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including:

EB 136 Tuesday January 28: WHO Engagement with Non-state Actors; US issues apology to the African Group

Posted on by Claire Cassedy

During Tuesday’s session of the WHO Executive Board, the board considered a proposal from Argentina on the table for a “Framework of Engagement with Non-state Actors.” Many states, both Board members and non-Executive Board member states, contributed to the discussion, citing the issue as a critical reform issue for the WHO. While a number of states took issue with some of the specifics of the draft proposal, for example that at current time all types of non-state actors were lumped together (i.e. Continue Reading →

EB 136 WHO Special Session: Unanimous Ebola Resolution [finally reached on Sunday]

Posted on by Claire Cassedy

On Sunday January 25, 2015, the WHO Executive Board unanimously approved the resolution, “Ebola: Ending the current outbreak, strengthening global preparedness, and ensuring WHO capacity to prepare for and respond to future large-scale outbreaks and emergencies with health consequences.” Though unanimous in the end, negotiations for the resolution took 4 days, the Friday session lasting until 5:45am on Saturday morning.

Continue Reading →

Obama officials seek end of WIPO program on limitations and exceptions to patent rights in developing countries

Posted on by Staff

During the WIPO 2014 General Assembly’s discussions of patents and health in the context of the work of the Standing Committee on the Law of Patent (SCP), the Obama Administration embraced an aggressive position against WIPO technical assistance on the use of patent limitations and exceptions.

Continue Reading →

New leak of TPP consolidated text on intellectual property provides details of pandering to drug companies and publishers

Posted on by James Love

For more information:
James Love, Knowledge Ecology International
email: james.love@keionline.org, +1.202.361.3040

The May 16, 2014 version of the consolidated negotiating text for the Intellectual Property Chapter for the Trans-Pacific Partnership (TPP) agreement is a long, complex document that taken as a whole is designed to expand and extend monopolies on knowledge goods, including in particular publisher-owned copyrights, patents on inventions, and monopoly rights in data used to register new drugs, vaccines and agricultural chemical products.

Continue Reading →

KEI Notes & Comments at TTIP Seventh Round of Negotiations at Stakeholder Event

Posted on by Claire Cassedy

The 7th Round of the negotiations of the Transatlantic Trade and Investment Partnership (TTIP) Agreement began Monday September 29, 2014 in the United States. This round’s paltry effort at transparency, the TTIP Stakeholder Engagement Day, was held at the suburban 4-H conference center in Chevy Chase, MD. Although the information packet for the event included public transport instructions, the location was difficult to access for any attendees without a car, and even then, parking was extremely limited. Continue Reading →

Bayer’s rejection of request for affordable Nexavar for Fathi Helmi Aboseda (Egypt)

Posted on by James Love

Today we received news from Nina Mahmud that her father-in-law, Fathi Helmi Aboseda, has passed away in Egypt. Mr. Aboseda was suffering from liver cancer. Earlier this year, Nina Mahmud had contacted Bayer and KEI asking for help in finding affordable copies of sorafenib, a drug for liver and kidney cancer sold by Bayer under the trade name Nexavar, a drug that was extending and improving the quality of his life. The price of Nexavar in Egypt was $900 per week, and Mr. Aboseda had used his entire life savings to buy the drug.

Continue Reading →

January 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer

Posted on by Thiru

On 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network: YP-CDN submitted a Proposal for the Inclusion of Trastuzumab in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Breast Cancer to WHO’s Exper Continue Reading →

KEI asks FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments

Posted on by James Love

July 15, 2014

Knowledge Ecology International (KEI) asks the FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments. Letter to FTC provides evidence of possible conspiracy to segment markets, involving licensing of an NIH funded invention for use in Europe, in return for abandoning efforts to enter US market.

For More Information:

James Love, Knowledge Ecology International
Email: james.love@keionline.org
Tel +1.202.332.2670
Cell +1.202.361.3040

Continue Reading →

© 2025 Knowledge Ecology International. All rights reserved.
Hiero by aThemes
hamamoto_lee_22sep2014_wipoga.jpg